Friday, April 1, 2022 Daily Archives

BioProcess Insider State of the Industry – Live from BPI West, March 2022

by

BioProcess Insider’s State of the Industry takes a deeper look into the recent business news affecting the biomanufacturing industry, picking apart the numbers and highlighting potential trends. With a panel of industry experts, editor Dan Stanton discusses recent mergers and acquisitions in the bioprocess space, bottlenecks within the manufacturing sector, the continued head- and tailwinds COVID-19 is placing on businesses, and the evolution of the cell and gene therapy landscape and what that means for supply chains. Panelists: Frank Orlowski,…

April 1, 2022

Intensifying Upstream Processing and the Implications for Media Management

by

Process intensification offers many benefits but implementing PI can introduce an unexpected challenge of managing larger media volumes. This whitepaper covers the implications of media management when developing PI strategies. Key Learning Objectives: Gain the tools and knowledge needed to confidently assess intensification options with a focus on media management for new or existing facilities. Follow the media journey from prep to use, exploring potential logistical pitfalls in the management of increased media volumes associated with process intensification. See how…

April 1, 2022

Abzena bags $65m to expand manufacturing capacity

by

Abzena has secured $65 million in additional funding to expand its production facilities to meet the increased demand in the industry. Contract development manufacturing organization (CDMO) Abzena says the latest investment from Welsh, Carson, Anderson & Stowe, and Biospring Partners will allow the firm to meet growing demand by increasing the capacity of its manufacturing capabilities for clinical and commercial supply. “At Abzena, we put patients at the center of all that we do. This new capital will allow us…

April 1, 2022

Bayer elusive on $2.2bn manufacturing revamp plan

by

Bayer says a three-year production reorganization will modernize its manufacturing network and streamline its supply chain, but specific details remain scarce. The Germany-headquartered biopharma firm announced “it is strengthening the production network of its pharmaceutical division†yesterday through a three-year, €2 billion ($2.2 billion) restructure plan. According to the release, “Bayer is planning to invest in its core manufacturing plants and strengthen their operational responsibilities to sustainably support the implementation of the company’s strategy for its pharmaceuticals business. A significant…

April 1, 2022